- YUTIQ Indicated for the Treatment of Chronic Non-Infectious Posterior Segment Uveitis - WATERTOWN, Mass. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic

– Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for Ocular Diseases - WATERTOWN, Mass. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to

- DEXYCU TM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQ TM commercial launch on track for 1Q19 -  WATERTOWN, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) --   EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing

WATERTOWN, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®

- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and

WATERTOWN, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned

WATERTOWN, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled

-YUTIQ ™ approved by U.S. FDA ; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ technology for posterior segment uveitis in Greater China - -Commercial preparations

WATERTOWN, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the

WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter of fiscal year 2019 on Tuesday, November 6 .

- Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

WATERTOWN, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data supporting the

- Five oral abstracts to be presented at annual meeting and subspecialty days – -24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company

- The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S.  - Company to host conference call today at 8:30 a.m. ET WATERTOWN, Mass. , Oct.

WATERTOWN, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of calendar year 2019 -Balance sheet strengthened by $35 million of capital led by EW

WATERTOWN, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its

WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved

WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal 2018 fourth quarter and full year on Wednesday,

WATERTOWN, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled